AbbVie Makes $63B Bid for Botox Maker Allergan - NBC Chicago
National & International News
The day’s top national and international news

AbbVie Makes $63B Bid for Botox Maker Allergan

Regulators and Allergan shareholders still need to approve the deal

    processing...

    NEWSLETTERS

    AbbVie Makes $63B Bid for Botox Maker Allergan
    AP
    This March 20, 2002 file photo shows a vial of Botox, made by Allergan. (AP Photo/Damian Dovarganes)

    AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at about $63 billion.

    The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45% premium to Allergan's closing price Monday.

    Shares of Allergan Plc, based in Dublin, Ireland, jumped nearly 30% before the opening bell.

    AbbVie shareholders will own 83% of the specialty drug company combination after the deal's completion while Allergan shareholders will have a 17% stake.

    Explaining the Yield Curve Inversion with Gummy Candy

    [NATL] Explaining the Yield Curve Inversion with Gummy Candy

    A yield curve inversion has been a reliable predictor in a coming recession, but what exactly is a yield curve inversion? We explain... using gummy candy.

    (Published Wednesday, Aug. 14, 2019)

    Regulators and Allergan shareholders still have to approve the deal.

    Shares of AbbVie Inc., based in North Chicago, Illinois, sank 10%.